I guess if anyone wanted to glean good news from the call.
- Investor updates qtrly along with regulatory filings. So the expectations are set.
The company wants to achieve credibility.
- Universities are reaching out to us to do studies with only the cost of the drug, possibly even trials funded by university depending on preliminary results
- Companies (yes plural) with NDAs for potential partnerships probably meaning due diligence from both sides being done, may come to fruition, may not, but opportunity is there.
- Nash coming soon per CR, he said he was excited about the data, but if i had a poker team, id want him on it because i dont know if he even has inflection in his voice to signal either way.
- strengthening board leadership with experience
- apparently a good pool of CEO possibilities

Those were the positives. The negatives are what we all read last night, the trial holds, low cash position and the wait to see if they can find a partner before cash runs out. Hopefully the renewed focus vs throwing leronlimab at every indication that pops up will yield positive results. If not, well then those that hold won't have to worry about planning those vegas trips.